Skin elasticity improvement

Skin elasticity improvement" refers to efforts or interventions aimed at enhancing or restoring the elastic resilience of skin, which naturally diminishes with aging and environmental damage. The concept is not attributable to a single molecular target, but rather involves a complex interplay of extracellular matrix proteins (especially elastin and collagen), enzymes (notably matrix metalloproteinases — MMPs), growth factors (such as transforming growth factor beta, TGF-β), fibroblasts, oxidative stress, and inflammatory pathways[1][2][3][5]. Loss of skin elasticity is primarily the result of: - Degradation and fragmentation of elastin fibers and collagen in the dermis. - Increased activity of proteolytic enzymes like matrix metalloproteinases. - Impaired signaling in pathways such as TGF-β/Smad that maintain extracellular matrix homeostasis. - Accumulation of advanced glycation end products (AGEs) and resultant fiber cross-linking. - Persistent low-level inflammation and oxidative stress, as well as the senescence of dermal cells[1][2][3][4][5]. Because "Skin elasticity improvement" is not itself a molecular entity, it cannot be classified within standard biological, molecular, or pharmacological taxonomies. Instead, it remains a therapeutic objective pursued by targeting several different recognizable molecules (e.g., MMPs, TGF-β receptor, elastin, collagen) and pathways.